{
    "body": "What is the mechanism of action of onartuzumab?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23922054", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22917884", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25806189", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27937096", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25074413", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27349303", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24101053", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27918764", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24687921", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26445503", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23894056", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25522765", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24493831", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25777467", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24258345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24959087", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27856142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23882082", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27401892", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27918718", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23063071", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23536720", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25818471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23810377"
    ], 
    "ideal_answer": [
        "Onartuzumab is monoclonal antibody targeting MET. It works by inhibiting MET. Onartuzumab was tested for treatment of non-small cell lung carcinoma, adenocarcinoma of the stomach and gastroesophageal Junction, and recurrent glioblastoma."
    ], 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228"
    ], 
    "type": "summary", 
    "id": "5890dcba621ea6ff7e000003", 
    "snippets": [
        {
            "offsetInBeginSection": 316, 
            "offsetInEndSection": 503, 
            "text": " In this study, e-training was used to train board-certified pathologists to evaluate non-small cell lung carcinoma for eligibility for treatment with onartuzumab, a MET-inhibiting agent.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27349303", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 156, 
            "text": "A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 238, 
            "offsetInEndSection": 331, 
            "text": "MET immunohistochemistry expression as a biomarker of onartuzumab activity was also examined.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1721, 
            "offsetInEndSection": 2173, 
            "text": "CONCLUSION: The addition of onartuzumab to mFOLFOX6 in gastric cancer did not improve efficacy in an unselected population or in a MET immunohistochemistry-positive population.IMPLICATIONS FOR PRACTICE: The YO28252 study demonstrated that the addition of the anti-MET agent onartuzumab to mFOLFOX6 for treatment of gastric cancer did not improve efficacy in an overall study population or those selected for positive MET status by immunohistochemistry.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 251, 
            "offsetInEndSection": 433, 
            "text": " The phase II study GO27819 investigated the monovalent MET inhibitor onartuzumab plus bevacizumab (Ona + Bev) versus placebo plus bevacizumab (Pla + Bev) in recurrent glioblastoma. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27918718", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 167, 
            "offsetInEndSection": 376, 
            "text": "We report results of METGastric, a phase 3 trial of the MET inhibitor onartuzumab plus standard first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative, MET-positive, advanced GEC.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27918764", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1678, 
            "offsetInEndSection": 1872, 
            "text": "Conclusion Onartuzumab plus erlotinib did not improve clinical outcomes, with shorter OS in the onartuzumab arm, compared with erlotinib in patients with MET-positive non-small-cell lung cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27937096", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 440, 
            "offsetInEndSection": 657, 
            "text": "A recent example of a failed trial is the Phase III MetLung trial that compared the effects of the c-MET monovalent antibody onartuzumab with erlotinib versus erlotinib alone in late-stage non-small-cell lung cancer. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25818471", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 132, 
            "text": "Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23882082", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 336, 
            "offsetInEndSection": 496, 
            "text": "Because onartuzumab, a monovalent antibody to MET, blocks HGF-induced MET activation, the addition of onartuzumab to erlotinib may improve therapeutic efficacy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25522765", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1118, 
            "offsetInEndSection": 1330, 
            "text": "Because binding of sMET to onartuzumab in circulation resulted in increasing sMET serum concentrations due to reduced clearance, this likely renders sMET unsuitable as a pharmacodynamic biomarker for onartuzumab.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258345", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 161, 
            "text": "Onartuzumab, a humanized, monovalent monoclonal anti-MET antibody, antagonizes MET signaling by inhibiting binding of its ligand, hepatocyte growth factor (HGF).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258345", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 131, 
            "text": "Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23882082", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 158, 
            "text": "Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24258345", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 193, 
            "text": "Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated for the treatment of solid tumors.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26445503", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 595, 
            "offsetInEndSection": 943, 
            "text": "Successful therapeutic targeting of the MET/HGF pathway has been achieved using monoclonal antibodies against the MET receptor and its ligand HGF in addition to MET-specific and multitargeted small-molecule tyrosine-kinase inhibitors with several drugs in late-phase clinical trials including onartuzumab, rilotumumab, tivantinib, and cabozantinib.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24959087", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1504, 
            "offsetInEndSection": 2091, 
            "text": "Grade 3-5 adverse events (AEs) were seen in 88.3% of patients receiving onartuzumab and in 78.3% of patients receiving placebo, with serious AEs in 55% and 40%, respectively.The addition of onartuzumab to mFOLFOX6 in gastric cancer did not improve efficacy in an unselected population or in a MET immunohistochemistry-positive population.The YO28252 study demonstrated that the addition of the anti-MET agent onartuzumab to mFOLFOX6 for treatment of gastric cancer did not improve efficacy in an overall study population or those selected for positive MET status by immunohistochemistry.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27401892", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 133, 
            "text": "Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23882082", 
            "endSection": "title"
        }
    ]
}